Incidence of second primary malignancies in metastatic castration-resistant prostate cancer: results from observational studies in three countries

This reports some of the first incidence rate (IR) estimates of second primary malignancies (SPMs) in men with metastatic castration-resistant prostate cancer (mCRPC) in three countries. Claims data from the German Pharmacoepidemiological Research Database; registry data from the Prostate Cancer Dat...

Full description

Saved in:
Bibliographic Details
Published in:Future oncology (London, England) England), 2020-09, Vol.16 (25), p.1889-1901
Main Authors: Vassilev, Zdravko P, Gabarró, Montse Soriano, Kaye, James A, Saltus, Catherine W, Riedel, Oliver, Scholle, Oliver, Mehtälä, Juha, Korhonen, Pasi, Garbe, Edeltraut, Zong, Jihong
Format: Article
Language:English
Subjects:
Ablation
Androgens
Cancer therapies
Disease
Epidemiology
healthcare data
Medicare
Metastasis
Observational studies
Patients
prognosis
Prostate cancer
risk estimate
second primary malignancies
Surveillance
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This reports some of the first incidence rate (IR) estimates of second primary malignancies (SPMs) in men with metastatic castration-resistant prostate cancer (mCRPC) in three countries. Claims data from the German Pharmacoepidemiological Research Database; registry data from the Prostate Cancer Data Base Sweden; and combined registry-claims data from the US Surveillance, Epidemiology and End Results-Medicare database were analyzed to obtain overall survival and incidence of SPMs in men with mCRPC. SPMs occurred in 308 German (n = 2360), 273 Swedish (n = 2849) and 172 US (n = 2234) men with mCRPC. IRs of SPMs were 79.0 (95% CI: 70.4–88.4), 101.7 (95% CI: 90.3–114.5) and 59 (95% CI: 50–68) per 1000 person-years in German, Swedish and US cohorts, respectively. These studies report some of the first IR estimates of SPMs in men with mCRPC, providing a historical risk estimate of SPM in this patient population.
ISSN:1479-6694
1744-8301
DOI:10.2217/fon-2020-0315